Passionate about health and ethics issues, I had the chance with Pharmion and then Celgene to participate in the advent of immunotherapy by participating in the marketing in France of Imids from the beginning of the 2000s.
I wish to see the cure of an increasing number of cancers and I do this by promoting the Good Use of drugs with as much scientific rationale as possible, thus guaranteeing the best benefit/risk ratio for patients.
Same missions as at Celgene. Sharing Celgene and BMS cultures. We have been pursuing the same objective for a long time: to understand Cancer and to fight against this disease for the good of patients, families and society.
2019/2021 Development of Imnovid (pomalidomide)
Result : 1st in France in terms of implementation and growth in 2021 on the Imnovid molecule, still in the top 3 in France since I have been in charge of this drug.
Leaving the company on December 21, 2021 - I realized that I was not cut out to work in large top-down structures. I am a deeply autonomous person who likes prospecting in large sectors and working upstream of the launches of innovative drugs with high added value in rare diseases. I stayed 17 years in this company, it was time for me to change.
